MAPT and Alzheimer disease: Overall, evidence shows a clear indication for the use of CSF biomarkers Aβ1–42, Aβ1–42/Aβ1–40 ratio, T-tau and P-tau181 as an efficient measure to confirm or rule out AD when other biomarkers are inconclusive.